- Acquired by -, Mar 2021
- Raised $760k funding round, Dec 2019
- Raised $4.5M funding round, Oct 2018
About
Wize Pharma is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including dry eye syndrome (DES) and other inflammatory conditions. Wize has in-licensed certain rights to purchase, market, sell, and distribute a formula known as LO2A, a drug developed for the treatment of DES and other ophthalmological illnesses, including CCH and Sjgrens syndrome. LO2A is currently registered and marketed in Germany and Switzerland for the treatment of DES; in Hungary for the treatment of DES, CCH, and Sjgrens; and in the Netherlands for the treatment of DES and Sjgrens. Wizes strategy involves engaging local or multinational distributors to handle the distribution of LO2A. The company has finished a phase 2 trial of LO2A for patients with CCH and is currently conducting a phase 4 study of LO2A for DES in patients with Sjgrens. LO2A was developed by Prof. Shabtay Dikstein of the Hebrew Universitys School of Pharmacy as a substitute for natural tears to lubricate and protect ocular surface tissues.
Funding history · 2 rounds · $5.2M total
Q&A
- What is Wize Pharma's primary focus?
- Wize Pharma is a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, including dry eye syndrome (DES) and other inflammatory conditions.
- What is LO2A and where is it marketed?
- LO2A is a drug developed for the treatment of DES and other ophthalmological illnesses. It is registered and marketed in Germany and Switzerland for DES; in Hungary for DES, CCH, and Sjogren's; and in the Netherlands for DES and Sjogren's.
- What is Wize Pharma's strategy for LO2A distribution?
- Wize Pharma's strategy involves engaging local or multinational distributors to handle the distribution of LO2A.
- What clinical trials has Wize Pharma completed or is currently conducting for LO2A?
- Wize Pharma has finished a phase 2 trial of LO2A for patients with CCH and is currently conducting a phase 4 study of LO2A for DES in patients with Sjogren's.
- Who developed LO2A?
- LO2A was developed by Prof. Shabtay Dikstein of the Hebrew University's School of Pharmacy.
- When was Wize Pharma founded?
- Wize Pharma was founded in June 1982.
- What is the employee count for Wize Pharma?
- Wize Pharma has 1-10 employees.
- What is the total amount of funding Wize Pharma has raised?
- Wize Pharma has raised a total of $5,210,000.
- When was Wize Pharma's last funding round?
- Wize Pharma's last funding round occurred in December 2019, raising $760,000.
Team · 1
Sectors & technology
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | wizepharma.com/ |
|---|---|
| linkedin.com/company/14780074 | |
| YouTube | youtube.com/channel/UCeMeglMf1CXpQadHQ-PH7Jg |
Identifiers & details
| Former names | Star Night Technologies, OphthaliX |
|---|---|
| Founded | 1982-6 |
| Employees (exact) | 3 |
| Status reason | Acquired (Inactive) by - on Mar 2021 - closed due to acquisition |
Acquisitions & public offerings
Acquired by - 2021-03
Radar intelligence
Web history (Wayback)
| Domain | wizepharma.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|